Heyholder
‹ Activism Filings

ENZYCHEM LIFESCIENCES CORPORATION Largest shareholder group amends share-backed loans; stake unchanged at 21.61%

ENZYCHEM LIFESCIENCES CORPORATION· Report on Large Shareholdings

AI summary · Not investment advice

The stake of Bridget Lifescience Co.,LTD and 8 related parties in ENZYCHEM LIFESCIENCES CORPORATION stays at 21.61%. Related parties amended share-backed loans covering 9,831,255 shares.

Total under contracts

9,831,255 shares

11.62%

Key facts

Stake
21.61%Previous 21.61% · 0.0%p
Reporting holder
Bridget Lifescience Co.,LTD and 8 related parties
Previous stake
21.61%
Purpose of holding
To influence management
Relationship with issuer
Largest shareholder
Report type
Amendment
Reason for report
Amendment of share-backed loan contracts of related parties
Previous shares held
18,294,481 shares
Shares held
18,294,481 sharesNo change
Reason for amendment
Amendment of share-backed loan contracts of related parties
Previous shares under major contracts
9,831,255 shares
Shares under major contracts
9,831,255 shares
Reporting obligation date
Oct 8, 2026

Commentary

AI commentary · Not investment advice

What happened

Bridget Lifescience Co.,LTD, the largest shareholder of ENZYCHEM LIFESCIENCES CORPORATION, and 8 related parties reported changes to share-backed loan contracts. No shares were traded. They still hold 18,294,481 shares, a 21.61% stake.

In the company's terms

The company has 84,640,235 voting shares. Of the group's shares, 9,831,255 (11.62%) are tied up in pledges and similar contracts, the same as in the previous report.

What changes for shareholders

Two contracts show change dates in this period. A related party pledged 1,614,161 shares to a bank for a KRW 460.0 million loan running to 2027.04.14. Another pledge of 2,200,000 shares to another bank secures KRW 350.0 million and runs to 2027.10.08. Both require a collateral maintenance ratio of 120%, meaning the shares must be worth at least that share of the loan. The other contracts are share-backed loans from individuals, with interest rates up to 12.0%.

Comments

No comments yet

Comments from shareholders will appear here.